Tesamorelin: What Lakeland Readers Should Know

Tesamorelin is the only peptide in its family with a current FDA approval, but that approval covers one narrow use. It is sometimes promoted for fat loss or anti-aging, which is outside its label. This page explains what the trials found and what they did not. It is general information, not advice for your situation.

What it is and how it works

Tesamorelin is a lab-made version of growth hormone-releasing hormone (GHRH), a brain hormone. It contains the full 44-amino-acid chain of human GHRH, with a small fatty chain added at one end to make it more stable.¹

It binds the same receptor on the pituitary gland as natural GHRH, with similar strength in lab tests. The pituitary then releases the body’s own growth hormone in pulses. Growth hormone helps break down fat and raises IGF-1 (insulin-like growth factor 1), a hormone made mostly by the liver.¹ The label notes no meaningful changes in other pituitary hormones.¹

It is given as an injection under the skin. Brand names are Egrifta and the newer Egrifta WR.

What the research shows (and where evidence is weak)

The trials behind the approval. FDA approval rests on two phase 3 trials (large trials that test whether a drug works before approval). They were randomized, double-blind and placebo-controlled, meaning neither patients nor staff knew who got the drug and who got a dummy shot. Together they enrolled 816 adults with HIV who had extra belly fat. Most were men, average age 48. People taking diabetes medicines were excluded. Each trial lasted 26 weeks, with a 26-week extension.¹²

What changed. Visceral fat is the deep fat around the organs, measured here by CT scan. After 26 weeks it fell about 12% to 20% more than with placebo, depending on the trial.¹² Body weight did not change compared with placebo. Waist size fell by only about 1 to 2 cm more than placebo, and fat under the skin of the belly did not change significantly.¹³ Triglycerides (a blood fat) improved, and people reported less distress about how their belly looked.³

It did not last after stopping. People switched to placebo for the second 6 months saw deep belly fat rise again by 16% to 22%. In those who kept taking it, the reduction held.¹³

Was it a real health benefit? The approved benefit is a smaller number on a scan in one specific group. The label says long-term heart safety has not been established.¹ Europe’s medicines committee said the fat reduction had “not been shown to be clinically meaningful in terms of actual health benefits.” It also called high IGF-1 “a major safety concern.” The company withdrew its European application in 2012.⁴

Other studies (not approved uses).

• In 61 adults with HIV and fatty liver, a 12-month trial found liver fat fell more than with placebo. This was a single study, and it measured liver fat, not liver disease outcomes.⁵
• In 152 adults aged 55 to 87, a 20-week trial found a modest effect on thinking-test scores, mainly planning and decision skills. It has not been confirmed. Mild side effects were reported by 68% on the drug versus 36% on placebo.⁶

No tesamorelin trial has studied healthy adults seeking fat loss or anti-aging.

FDA and regulatory status

FDA-approved for one use. As of the Egrifta WR label revised in March 2025, tesamorelin is indicated “for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.” First U.S. approval was in 2010. The label states it is not indicated for weight-loss management because it has a weight-neutral effect, and that long-term cardiovascular safety has not been established.¹ Use for anything else is off-label.

Europe. The application was withdrawn in 2012 while the expert committee held a provisional view that it could not be approved.⁴

Unapproved “research” products. In August 2026, FDA sent a warning letter to a Florida online seller. It said that seller’s tesamorelin product, among others, was an unapproved new drug, despite “research use only” labels.⁷ These products are not the FDA-approved drug. See research-chemical peptide risks.

Sport. The World Anti-Doping Agency’s 2026 Prohibited List names tesamorelin among GHRH analogues that are banned at all times.⁸

Compounding. As of May 14, 2026, tesamorelin is not on FDA’s list of drugs barred from compounding because they were found unsafe or ineffective. It is also not in any of FDA’s 503A nomination categories.⁹¹⁰ Under federal law, a traditional (503A) pharmacy may compound from a substance that is a component of an FDA-approved drug, if other conditions are met.¹¹ A compounded product is still not FDA-approved. Florida pharmacy and prescribing rules also apply; see are peptides legal in Florida?.

Common side effects and safety

From the FDA label:¹

• Raised IGF-1. After 26 weeks, 47% of treated patients had IGF-1 well above the normal range, and 36% had it very far above. The label says the effects of long-term high IGF-1 are unknown and calls for monitoring.
• Blood sugar. 5% of treated patients reached a diabetes-range HbA1c (a 3-month blood sugar measure) versus 1% on placebo.
• Fluid retention. Swelling, joint pain and carpal tunnel symptoms. These usually went away or ended after stopping.
• Injection-site reactions in 25% versus 14% on placebo, and allergic-type reactions in 4%.
• Common side effects more often than placebo: joint pain, limb pain, muscle pain and swelling in the legs or arms.
• Do not use with a damaged pituitary system (such as after pituitary surgery or head radiation), active cancer, or in pregnancy. Cancer risk is a label warning.

About half of patients developed antibodies to the drug. Responses looked similar with or without them.¹

Typical cost range

No official list price was found in this research. Because it is FDA-approved, insurance may cover it for the labeled use, subject to the plan’s rules. Coverage for other uses is less likely. Ask your insurer about coverage, and ask any provider or pharmacy for a written price breakdown before you start. See our cost guide and insurance and HSA/FSA guide.

Questions to ask a provider

• Do I have the condition tesamorelin is approved for? If not, why do you recommend it?
• Is this the FDA-approved product from a pharmacy, or something else? See compounded vs. FDA-approved peptides.
• How will you check my IGF-1 and blood sugar, and how often?
• What happens if I stop? The trial benefit faded after stopping.
• Do I have any history of cancer, diabetes, eye disease or pituitary problems that matters here?
• Are there other options to consider? See peptides vs. TRT and HRT.
• What will it cost per month, and will my insurance cover it?